Experimental antibody targets advanced cancers in new trial
NCT ID NCT04452955
Summary
This study is testing an experimental antibody called PRL3-Zumab in patients with advanced solid tumors that cannot be surgically removed or have spread. The treatment is given through an IV every two weeks to see if it can slow tumor growth and improve survival. Researchers will monitor how patients respond to the treatment and track any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89014, United States
-
HonorHealth Research
Scottsdale, Arizona, 85258, United States
-
Norton Healthcare
Louisville, Kentucky, 40200, United States
-
St. Jude Medical Center
Fullerton, California, 92835, United States
-
The Angeles Clinic
Los Angeles, California, 90025, United States
Conditions
Explore the condition pages connected to this study.